Nina Stuhldreher1, Eric Leibing2, Falk Leichsenring3, Manfred E Beutel4, Stephan Herpertz5, Juergen Hoyer6, Alexander Konnopka7, Simone Salzer2, Bernhard Strauss8, Joerg Wiltink4, Hans-Helmut König7. 1. Department of Health Economics and Health Services Research, Hamburg Center for Health Economics (HCHE), University Medical Center Hamburg-Eppendorf, Germany. Electronic address: n.stuhldreher@uke.de. 2. Department of Psychosomatic Medicine and Psychotherapy, University Medicine, Georg-August-University Goettingen, Germany. 3. Clinic of Psychosomatics and Psychotherapy, Justus-Liebig-University Giessen, Germany. 4. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Germany. 5. Department of Psychosomatic Medicine and Psychotherapy, LWL-University Clinic Bochum, Ruhr-University Bochum, Germany. 6. Clinical Psychology and Psychotherapy and Clinic for Psychotherapy and Psychosomatic Medicine, Technische Universitaet Dresden, Germany. 7. Department of Health Economics and Health Services Research, Hamburg Center for Health Economics (HCHE), University Medical Center Hamburg-Eppendorf, Germany. 8. Institute of Psychosocial Medicine and Psychotherapy, University Hospital, Jena, Germany.
Abstract
BACKGROUND: Social anxiety disorder (SAD) is associated with low direct costs compared to other anxiety disorders while indirect costs tend to be high. Mental comorbidities have been identified to increase costs, but the role of symptom severity is still vague. The objective of this study was to determine the costs of SAD, and to explore the impact of symptoms and comorbidities on direct and indirect costs. METHODS: Baseline data, collected within the SOPHO-NET multi-centre treatment study (N=495), were used. Costs were calculated based on health care utilization and lost productivity. Symptom severity was measured with the Liebowitz-Social-Anxiety-Scale; comorbidities were included as covariates. RESULTS: Total 6-month costs were accrued to €4802; 23% being direct costs. While there was no significant association with SAD symptom severity for direct costs, costs of absenteeism increased with symptom severity in those with costs >0; comorbid affective disorders and eating disorders had an additional effect. Self-rated productivity was lower with more pronounced symptoms even after controlling for comorbidities. LIMITATIONS: As the study was based on a clinical sample total costs were considered, rather than net costs of SAD and no population costs could be calculated. DISCUSSION: The burden associated with lost productivity was considerable while costs of healthcare utilization were rather low as most patients had not sought for treatment before. Efforts to identify patients with SAD earlier and to provide adequate treatment should be further increased. Mental comorbidities should be addressed as well, since they account for a large part of indirect costs associated with SAD.
BACKGROUND:Social anxiety disorder (SAD) is associated with low direct costs compared to other anxiety disorders while indirect costs tend to be high. Mental comorbidities have been identified to increase costs, but the role of symptom severity is still vague. The objective of this study was to determine the costs of SAD, and to explore the impact of symptoms and comorbidities on direct and indirect costs. METHODS: Baseline data, collected within the SOPHO-NET multi-centre treatment study (N=495), were used. Costs were calculated based on health care utilization and lost productivity. Symptom severity was measured with the Liebowitz-Social-Anxiety-Scale; comorbidities were included as covariates. RESULTS: Total 6-month costs were accrued to €4802; 23% being direct costs. While there was no significant association with SAD symptom severity for direct costs, costs of absenteeism increased with symptom severity in those with costs >0; comorbid affective disorders and eating disorders had an additional effect. Self-rated productivity was lower with more pronounced symptoms even after controlling for comorbidities. LIMITATIONS: As the study was based on a clinical sample total costs were considered, rather than net costs of SAD and no population costs could be calculated. DISCUSSION: The burden associated with lost productivity was considerable while costs of healthcare utilization were rather low as most patients had not sought for treatment before. Efforts to identify patients with SAD earlier and to provide adequate treatment should be further increased. Mental comorbidities should be addressed as well, since they account for a large part of indirect costs associated with SAD.
Authors: Abhishek Jaiswal; Shubham Manchanda; Vaishali Gautam; Akhil D Goel; Jitender Aneja; Pankaja R Raghav Journal: J Family Med Prim Care Date: 2020-07-30
Authors: Ifigeneia Mavranezouli; Evan Mayo-Wilson; Sofia Dias; Kayleigh Kew; David M Clark; A E Ades; Stephen Pilling Journal: PLoS One Date: 2015-10-27 Impact factor: 3.240
Authors: Anders Brantnell; Joanne Woodford; Enrico Baraldi; Theo van Achterberg; Louise von Essen Journal: J Med Internet Res Date: 2020-08-12 Impact factor: 5.428